190786-43-7

Basic information

• Product Name: BEPOTASTINE
• Synonyms: 4-(4-[(1S)(4-CHLOROPHENYL)-2-PYRIDYLMETHOXY]PIPERIDYL)BUTANOIC ACID;(+)-(S)-4-[4-[1-(4-Chloroph-enyl)-1-(2-pyridyl)Methoxy]pip-eridin-1-yl]butyric acid(Bopotastine base;(S)-4-[4-(4-Chlorophenyl-2-pyridylMethoxy)piperidinyl]butyric Acid Benzenesulfonate-d4;4-[(S)-(4-Chlorophenyl)-2-pyridinylMethoxy]-1-piperidinebutanoic Acid Benzenesulfonate-d4;BB-d4;Bepotastine Benzenesulfonate-d4;Bepotastine-d4 Besylate;(S)-4-(4-((4-chlorophenyl)(pyridin-2-yl)Methoxy)piperidin-1-yl)butanoic acid
• CAS NO: 190786-43-7
• Molecular Formula: C21H25ClN2O3
• Molecular Weight: 388.89
• EINECS: 1533716-785-6
• Product Categories: Active Pharmaceutical Ingredients
• Mol File: 190786-43-7.mol
• Article Data: 18

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BEPOTASTINE(CAS DataBase Reference)
• NIST Chemistry Reference: BEPOTASTINE(190786-43-7)
• EPA Substance Registry System: BEPOTASTINE(190786-43-7)

Safety Data

• Hazardous Substances Data: 190786-43-7(Hazardous Substances Data)

Usage

Description

Bepotastine is a histamine H1 receptor antagonist, which is primarily used to treat various allergic conditions. It works by blocking the action of histamine, a substance released during an allergic response, thereby reducing the symptoms associated with allergies.

Uses

Used in Pharmaceutical Industry:
Bepotastine is used as an anti-allergic agent for the treatment of allergic rhinitis, chronic urticaria, and pruritus associated with skin conditions such as eczema/dermatitis, prurigo, or pruritus cutaneus. It helps suppress the allergic inflammatory processes by blocking the histamine H1 receptors, providing relief from allergy symptoms.

Originator

Bepotastine,Ube

Therapeutic Function

Antiallergic

Upstream product

• 190786-43-7 4-(4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl)butanoic acid 
• 142404-69-1 2-[chloro(4-chlorophenyl)methyl]pyridine 
• 125602-67-7 ethyl 3-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-1-piperidyl]propionate 
• 27652-89-7 (4-chlorophenyl)-2-pyridylmethanol 
• 207726-35-0 4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidine-1-carboxylic acid ethyl ester 
• 210095-55-9 (S)-(-)-2-((4-chlorophenyl)(piperidin-4-yloxy)methyl)pyridine 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 4045-22-1 N-acetyl-4-hydroxypiperidine 
• 1560797-69-4 (S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino] butyric acid D-menthyl ester 
• 1560797-70-7 (S)-4-{4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino}butyric acid D-menthyl ester L-tartrate 
• 1560797-65-0 (RS)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid D-menthyl ester 
• 122368-54-1 4-[(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidine 
• 1092777-17-7 (S)-bepotastine L-menthyl ester 

Downstream Products

• 125602-71-3 [14C]-Bepotastine besilate 

Relevant articles and documents

Total synthesis method of bestatin

The method comprises the following steps: (4 - chlorophenyl) (2 - pyridyl) - methanol as a starting raw material, and sequential addition reaction. Examples of the etherification reaction include a deprotection reaction, a chiral resolution, a condensation reaction, a hydrolysis reaction, and the like. The synthesis method has the advantages of cheap and easily available raw materials, no need of expensive chiral catalysts, simpler synthesis method, mild conditions, less side reactions and low cost.

Identification, Characterization and HPLC Quantification of Process-Related Impurities in Bepotastine Besilate Bulk Drug

Bepotastine besilate (here after referred to as BTST), chemically known as ({d(S)4[4[(4chlorophenyl) (2pyridyl) methoxy] piperidino} butyric acid monobenzene sulphonate), is a second-generation antihistamine drug. To the best of our knowledge, no studies concerning the isolation or identification of process-related impurities have been reported so far. The current study reports the development and validation of a stability-indicating RP-HPLC method for the separation and identification of 5 potential impurities in bepotastine besilate. In this experiment, the structures of 3 process-related impurities were found to be new compounds. They were characterized and confirmed by NMR and MS spectroscopy analyses. These 3 new compounds were proposed to be (S)-4-[(phenyl)-2-pyridinylmethoxy]-1-piperidinebutanoic acid,(Imp-A); 4-[(S)-(4-chlorophenyl)-2-pyridinylmethoxy]-1- piperidinebutyric acid, N-oxide (Imp-B) and (S)-4-[(4- chlorophenyl)-2-pyridinylmethoxy]-1-piperidylethane (Imp-C). In addition, an efficient optimized chromatographic method was performed on a Shimadzu Inertsil C8-3 column (150 mm×4.6 mm, 3 μm) to separate and quantify these 5 impurities. It was using 15 mmol ammonium formate buffer in water (pH adjusted to 3.8 with formic acid) and acetonitrile as the mobile phase in gradient mode. The method was developed to separate and quantify these 5 impurities obtained in the range of 0.05-0.75 μg/mL. It was validated and proven to be selective, accurate and precise and suitable. It is the first publication of identification and characterization data of the 3 new compounds. It is also the first effective HPLC method for separation and quantification of all of process-related impurities in bepotastine besilate.